Prenosis to provide enhanced Sepsis identification in remote environments with portable “Prenostics”, promising a new era of preemptive and precise diagnostic testing
CHICAGO, Nov. 17, 2021 /PRNewswire/ — Prenosis, Inc., a precision diagnostics company transforming clinical diagnosis with predictive intelligence, announced today that the Defense Threat Reduction Agency (DTRA), a U.S. Department of Defense agency that confronts emerging threats, awarded the company up to $4.3 million for further development of point-of-care technology for the early detection of sepsis for warfighters in the field.
Warfighters in the field can often be exposed to infections, which can rapidly lead to life-threatening complications, including sepsis. It is currently difficult to identify which warfighters are at highest risk of sepsis, due to both the usual lack of practical access to a centralized clinical lab and the lack of accurate sepsis diagnostics in general. Timely and accurate identification of warfighters with the highest chance of deterioration due to sepsis could enable earlier medical evacuations and life-saving treatments. Chances of sepsis mortality have been reported to increase by 8% per hour if left untreated[1], highlighting the need to identify and treat these cases as early as possible.
Prenosis has developed its Immunix™ Emergency Point-of-Care (ePOC) system to meet this critical need.